GeoVax Labs, Inc. is undergoing a significant leadership transition with the recent resignation of its Chief Financial Officer (CFO), Mark W. Reynolds. This change, effective November 13, 2026, comes at a pivotal time for the company as it continues to navigate the challenges of the pharmaceutical preparations sector.
Reynolds, who also served as Corporate Secretary and held other officer positions, has stepped down from all roles within the company and its subsidiaries. The Board of Directors swiftly appointed Anna Skowron as the new interim CFO, effective November 16, 2026. Skowron brings a wealth of experience from her previous roles, including serving as a director at BPC Consulting Ltd. and interim CFO at GridAI Technologies Corp.
This leadership change is particularly important for GeoVax Labs, which is focused on developing innovative vaccines and treatments. The pharmaceutical industry is highly competitive, and maintaining strong financial oversight is crucial for the company's success and investor confidence.
Background
GeoVax Labs, Inc., incorporated in Delaware, operates in the pharmaceutical preparations sector, classified under SIC code 2834. The company is publicly traded on the Nasdaq under the ticker symbol GOVX. Recent filings indicate ongoing activity, including a 10-Q report filed on November 12, 2026, and several 8-K filings detailing various corporate actions.
What the Filing Says
The recent 8-K filing reveals that Reynolds resigned from his position as CFO and Corporate Secretary on November 13, 2026. The filing states, “On November 14, 2026, the Board appointed Anna Skowron as Chief Financial Officer of the Company, effective as of November 16, 2026.”
Furthermore, the filing outlines the terms of Skowron's appointment, indicating that she will serve as the principal financial officer and principal accounting officer. Her consulting agreement with BPC Consulting Ltd. includes a monthly fee of $10,000, with potential performance-based bonuses tied to the completion of the company’s annual report.
Impact
This leadership transition may affect various stakeholders within the company, including employees, investors, and partners. The appointment of Skowron, who has extensive experience in financial consulting and corporate governance, aims to provide stability and continuity as GeoVax Labs progresses through its current projects and initiatives.
Additionally, the termination of Kelly T. McKee, M.D., as Chief Medical Officer on November 17, 2026, adds another layer of change within the company’s leadership structure. Such changes can create uncertainty, but they also present an opportunity for new strategies and directions.
What's Next
The filing does not specify what happens next regarding further leadership changes or strategic initiatives. However, the company is expected to continue its focus on developing its vaccine and therapeutic pipeline, which will be crucial for its growth and competitive positioning in the pharmaceutical industry.
Read Next
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction
Orchestra BioMed CFO Acquires Shares in Recent Filing
Upwork CFO Erica Gessert Reports Major Stock Transactions




